Key Insights

Highlights

Success Rate

94% trial completion (above average)

Published Results

12 trials with published results (19%)

Research Maturity

51 completed trials (82% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

4.8%

3 terminated out of 62 trials

Success Rate

94.4%

+7.9% vs benchmark

Late-Stage Pipeline

40%

25 trials in Phase 3/4

Results Transparency

24%

12 of 51 completed with results

Key Signals

12 with results94% success

Data Visualizations

Phase Distribution

55Total
Not Applicable (11)
P 1 (12)
P 2 (7)
P 3 (22)
P 4 (3)

Trial Status

Completed51
Unknown4
Terminated3
Withdrawn2
Recruiting2

Trial Success Rate

94.4%

Benchmark: 86.5%

Based on 51 completed trials

Clinical Trials (62)

Showing 20 of 20 trials
NCT05468619Phase 1CompletedPrimary

Neonatal Phase 1 Valacyclovir Study

NCT06134492Phase 3Recruiting

Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BAL

NCT05298254Phase 1CompletedPrimary

A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes

NCT05989672Phase 1CompletedPrimary

A Study on the Reactogenicity, Safety and Immune Response of a Targeted Immunotherapy Against HSV in Healthy Japanese Participants Aged 18-40 Years

NCT04065971Phase 4RecruitingPrimary

Randomized, Placebo-controlled, Double-blind Study of 2LHERP® in Orofacial Herpes Infections.

NCT01959295Phase 3CompletedPrimary

Phase III Study of ASP2151 in Herpes Simplex Patients

NCT02209324Phase 3CompletedPrimary

Open-label Study of ASP2151 in Herpes Simplex Patients

NCT04239521Completed

The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata

NCT00000985Phase 3CompletedPrimary

Comparison of Foscarnet Versus Vidarabine in the Treatment of Herpes Infection in Patients With AIDS Who Have Not Had Success With Acyclovir

NCT00001054Phase 1WithdrawnPrimary

The Safety and Effectiveness of Valacyclovir HCl in the Treatment of Herpes Simplex or Varicella/Zoster Infections in HIV-1 Infected Children

NCT00000635Not ApplicableCompletedPrimary

Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical Trifluridine

NCT04762511Phase 1TerminatedPrimary

A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years

NCT04664127Completed

Study of the Efficacy and Safety of Combined Treatment of Patients With Severe Herpes Simplex (HSV) Infection by Valacyclovir and Interferon Inducer Kagocel

NCT02685956CompletedPrimary

Clinical Evaluation of the Sentosa SA HSV1/2 Qualitative PCR Test

NCT02997982Phase 2Completed

Feasibility and Effects of Valaciclovir Treatment in Persons With Early Alzheimer's Disease

NCT00224484Phase 3CompletedPrimary

Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old

NCT00530777Phase 2Completed

HSV-2 Suppression to Reduce Maternal HIV-1 RNA Levels During Pregnancy and Breastfeeding

NCT01602562Phase 3CompletedPrimary

Valaciclovir Hydrochloride Phase III for Hematopoietic Stem Cell Transplantation Patients

NCT00855309Phase 3CompletedPrimary

Acyclovir in Preventing Herpes Simplex Virus Infection in Patients With Neutropenia

NCT00297206Phase 1CompletedPrimary

A Safety And Tolerability Study Of Valaciclovir Oral Suspension In Infants And Children

Scroll to load more

Research Network

Activity Timeline